Adult ADHD pp 101-168 | Cite as

Treatment

  • J. J. Sandra Kooij
Chapter

Abstract

This chapter guides the reader through the first part of the treatment of ADHD in adults. Treatment always starts with psychoeducation, and the special attitude of the therapist treating patients with ADHD is first discussed. Frequent asked questions and answers about ADHD and the treatment are addressed, as well as different forms of psychoeducation to patients and to the public, and at different phases of the treatment. Psychoeducation is regarded as a continuous process to empower patients to make their own well-informed decisions during treatment.

The part on medication treatment gives an overview of the available medications for ADHD. The effect of medication on the brain and on addiction is discussed. The order of treatment in case of comorbidity, how to deal with alcohol and cannabis use while on medication, contraindications, the physical exam before starting, measures to evaluate efficacy, dosing, and duration of action of different short- and long-acting stimulant preparations are all reviewed, as well as how to deal with pregnancy and driving issues while using medication for ADHD. The combination of stimulants with other psychopharmacotherapeutical treatments and finally treatment with melatonin for the delayed sleep phase in ADHD are described in a practical way for everyday clinical practice. Finally, the place of complementary and alternative treatments is shortly reviewed.

Keywords

Depression Cocaine Noradrenalin Risperidone Clonidine 

References

  1. Adler L, Dietrich A, Reimherr FW, Taylor LVM, Sutton VK, Bakken R, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006;18(2):107–13.PubMedGoogle Scholar
  2. Adler LA, Spencer TJ, Levine LR, Ramsey JL, Tamura R, Kelsey D, et al. Functional outcomes in the treatment of adults with ADHD. J Atten Disord. 2008;11(6):720–7.PubMedGoogle Scholar
  3. Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212–21.PubMedGoogle Scholar
  4. Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(5):841–5.PubMedGoogle Scholar
  5. Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S. Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):145–9.PubMedGoogle Scholar
  6. Amons P, Kooij J, Haffmans P, Hoffman T, Hoencamp E. Seasonality of mood disorders in adults with lifetime attention-deficit/hyperactivity disorder (ADHD). J Affect Disord. 2006;91(2–3):251–5.PubMedGoogle Scholar
  7. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5(4):525–39.PubMedGoogle Scholar
  8. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I102–16.PubMedGoogle Scholar
  9. Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17(4):407–20.PubMedGoogle Scholar
  10. Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf. 2008a;31(4):345–54.PubMedGoogle Scholar
  11. Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008b;47(2):209–18.PubMedGoogle Scholar
  12. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1–10.PubMedGoogle Scholar
  13. Barkley RA. ADHD and the nature of self-control. New York: The Guilford Press; 1997a.Google Scholar
  14. Barkley RA. Age dependent decline in ADHD: true recovery or statistical illusion? ADHD Rep. 1997b;5:1–5.Google Scholar
  15. Barkley RA, Murphy KR. Attention-deficit hyperactivity disorder, 3rd ed.: A clinical workbook. Guilford Publications; 2006.Google Scholar
  16. Barkley RA, Murphy KR, Dupaul GJ, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002;8(5):655–72.PubMedGoogle Scholar
  17. Barkley RA, Murphy KR, O’Connell T, Connor DF. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder. J Safety Res. 2005;36(2):121–31.PubMedGoogle Scholar
  18. Barkley RA, O’Connell T, Murphy KR, Anderson D, Connor DF. Effects of two doses of alcohol on simulator driving performance in adults with attention-deficit/hyperactivity disorder. Neuropsychology. 2006;20(1):77–87.PubMedGoogle Scholar
  19. Bekker EM, Kooij JJS, Buitelaar JK. Sleep and quality of life in ADHD. In: Verster J, editor. Sleep and quality of life in medical illness. Totowa: Humana Press; 2008.Google Scholar
  20. Berman T, Douglas VI, Barr RG. Effects of methylphenidate on complex cognitive processing in attention-deficit hyperactivity disorder. J Abnorm Psychol. 1999;108(1):90–105.PubMedGoogle Scholar
  21. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989a;28(5):777–84.PubMedGoogle Scholar
  22. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS, Goldblatt A. A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry. 1989b;28(6):903–11.PubMedGoogle Scholar
  23. Biederman J, Faraone S, Milberger S, Curtis S, Chen L, Marrs A, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1996a;35(3):343–51.PubMedGoogle Scholar
  24. Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996b;53(5):437–46.PubMedGoogle Scholar
  25. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2004;7(1):77–97.PubMedGoogle Scholar
  26. Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):16–25.PubMedGoogle Scholar
  27. Biederman J, Arnsten AF, Faraone SV, Doyle AE, Spencer TJ, Wilens TE, et al. New developments in the treatment of ADHD. J Clin Psychiatry. 2006;67(1):148–59.PubMedGoogle Scholar
  28. Biederman J, Wilens TE, Spencer TJ, Adler LA. Diagnosis and treatment of adults with attention-deficit/hyperactivity disorder. CNS Spectr. 2007;12(4 Suppl 6):1–15.Google Scholar
  29. Biederman J, Melmed RD, Patel A, McBurnett K, Donahue J, Lyne A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008a;13(12):1047–55.PubMedGoogle Scholar
  30. Biederman J, Seidman LJ, Petty CR, Fried R, Doyle AE, Cohen DR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008b;69(7):1150–6.PubMedGoogle Scholar
  31. Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr. 2008c;152(3):394–9.PubMedGoogle Scholar
  32. Blick SK, Keating GM. Lisdexamfetamine. Paediatr Drugs. 2007;9(2):129–35; discussion 136–128.PubMedGoogle Scholar
  33. Brue AW, Oakland TD. Alternative treatments for attention-deficit/hyperactivity disorder: does evidence support their use? Altern Ther Health Med. 2002;8(1):68–70, 72–64.PubMedGoogle Scholar
  34. Brue AW, Oakland TD, Evans RA. The use of a dietary supplement combination and an essential fatty acid as an alternative and complementary treatment for children with attention-deficit/hyperactivity disorder. Sci Rev Altern Med. 2001;5(4):187–94.Google Scholar
  35. Buhagiar K, Cassar J. Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature. Turk Psikiyatri Derg. 2007;18(2):179–83.PubMedGoogle Scholar
  36. Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, et al. A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2004;13(4):249–57.PubMedGoogle Scholar
  37. Carlson GA, Loney J, Salisbury H, Kramer JR, Arthur C. Stimulant treatment in young boys with symptoms suggesting childhood mania: a report from a longitudinal study. J Child Adolesc Psychopharmacol. 2000;10(3):175–84.PubMedGoogle Scholar
  38. Carlson PJ, Merlock MC, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord. 2004;6(5):416–20.PubMedGoogle Scholar
  39. Carpentier PJ. Pharmacotherapy for ADHD with addiction, in Dutch. Psyfar Nascholingstijdschrift over Psychofarmacologie. 2007;2(4):46–8.Google Scholar
  40. Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction. 2005;100(12):1868–74.PubMedGoogle Scholar
  41. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27(2):189–200.PubMedGoogle Scholar
  42. Chamberlain SR, Del Campo N, Dowson J, Muller U, Clark L, Robbins TW, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry. 2007;62(9):977–84.PubMedGoogle Scholar
  43. Chamorro L, Lopez I. Treatment of the attention deficit disorder (residual type) with moclobemide. Eur Psychiatry. 1995;10(2):112.PubMedGoogle Scholar
  44. Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood ­attention and hyperactivity problems. J Dev Behav Pediatr. 2003;24(1):4–8.PubMedGoogle Scholar
  45. Connor DF, Steingard RJ. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs. 2004;18(14):1011–30.PubMedGoogle Scholar
  46. Conway J, Wong KK, OíConnell C, Warren AE. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory. Pediatrics. 2008;122(4):e828–34.PubMedGoogle Scholar
  47. Coulter MK, Dean ME. Homeopathy for attention deficit/hyperactivity disorder or hyperkinetic disorder. Cochrane Database Syst Rev. 2007;17(4): CD005648.Google Scholar
  48. Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J Nerv Ment Dis. 2000;188(4):230–4.PubMedGoogle Scholar
  49. Cox DJ, Humphrey JW, Merkel RL, Penberthy JK, Kovatchev B. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract. 2004a;17(4):235–9.PubMedGoogle Scholar
  50. Cox DJ, Merkel RL, Penberthy JK, Kovatchev B, Hankin CS. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatry. 2004b;43(3):269–75.PubMedGoogle Scholar
  51. Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006a;118(3):e704–10.PubMedGoogle Scholar
  52. Cox DJ, Punja M, Powers K, Merkel R, Burket R, Moore M, et al. Manual transmission enhances attention and driving performance of ADHD adolescent males: pilot study. J Atten Disord. 2006b;10(2):212–6.PubMedGoogle Scholar
  53. Daviss WB, Birmaher B, Diler RS, Mintz J, Spencer TJ. Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression? Treatment of adult ADHD and comorbid depression. J Child Adolesc Psychopharmacol. 2008;18(3):257–64.PubMedGoogle Scholar
  54. Debooy VD, Seshia MM, Tenenbein M, Casiro OG. Intravenous pentazocine and methylphenidate abuse during pregnancy. Maternal lifestyle and infant outcome. Am J Dis Child. 1993;147(10):1062–5.PubMedGoogle Scholar
  55. Dodson WW. Pharmacotherapy of adult ADHD. J Clin Psychol. 2005;61(5):589–606.PubMedGoogle Scholar
  56. Dopfel RP, Schulmeister K, Schernhammer ES. Nutritional and lifestyle correlates of the cancer-protective hormone melatonin. Cancer Detect Prev. 2007;31(2):140–8.PubMedGoogle Scholar
  57. Dresel S, Krause J, Krause KH, LaFougere C, Brinkbaumer K, Kung HF, et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med. 2000;27(10):1518–24.PubMedGoogle Scholar
  58. Durst R, Rebaudengo-Rosca P. Attention deficit hyperactivity disorder, facilitating alcohol and drug abuse in an adult. Harefuah. 1997;132(9):618–22, 680.PubMedGoogle Scholar
  59. Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36(2):141–55.PubMedGoogle Scholar
  60. Faraone SV. Attention deficit hyperactivity disorder in adults: implications for theories of diagnosis. Curr Dir Psychol Sci. 2000;9:33–6.Google Scholar
  61. Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother. 2008;9(9):1565–74.PubMedGoogle Scholar
  62. Faraone SV, Biederman J. Efficacy of adderall for attention-deficit/hyperactivity disorder: a meta-analysis. J Atten Disord. 2002;6(2):69–75.PubMedGoogle Scholar
  63. Faraone SV, Upadhyaya HP. The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. J Clin Psychiatry. 2007;68(11):e28.PubMedGoogle Scholar
  64. Faraone SV, Short EJ, Biederman J, Findling RL, Roe C, Manos MJ. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int J Neuropsychopharmacol. 2002;5(2):121–9.PubMedGoogle Scholar
  65. Faraone SV, Sergeant J, Gillberg C. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2:104–13.PubMedGoogle Scholar
  66. Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Funct. 2005a;1:16.PubMedGoogle Scholar
  67. Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, et al. Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005b;15(4):664–70.PubMedGoogle Scholar
  68. Faraone SV, Biederman J, Doyle A, Murray K, Petty C, Adamson JJ, et al. Neuropsychological studies of late onset and subthreshold diagnoses of adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006a;60(10):1081–7.PubMedGoogle Scholar
  69. Faraone SV, Biederman J, Spencer T, Mick E, Murray K, Petty C, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006b;163(10):1720–9.PubMedGoogle Scholar
  70. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994–1009.PubMedGoogle Scholar
  71. Fayyad J, de Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9.PubMedGoogle Scholar
  72. Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry. 2004;65(11):1520–4.PubMedGoogle Scholar
  73. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry. 1996;57(5):184–9.PubMedGoogle Scholar
  74. Findling RL, Bukstein OG, Melmed RD, Lopez FA, Sallee FR, Arnold LE, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(1):149–59.PubMedGoogle Scholar
  75. Furara SA, Carrick P, Armstrong D, Pairaudeau P, Pullan AM, Lindow SW. The outcome of pregnancy associated with amphetamine use. J Obstet Gynaecol. 1999;19(4):377–80.PubMedGoogle Scholar
  76. Gadow KD, Sverd J. Attention deficit hyperactivity disorder, chronic tic disorder, and methylphenidate. Adv Neurol. 2006;99:197–207.PubMedGoogle Scholar
  77. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Grossman S. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56(4):330–6.PubMedGoogle Scholar
  78. Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W, et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. J Child Adolesc Psychopharmacol. 2003;13(2):123–36.PubMedGoogle Scholar
  79. Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of adolescents with attention deficit disorder. Am J Psychiatry. 1984;141(7):906–8.PubMedGoogle Scholar
  80. Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006;40(6):1134–42.PubMedGoogle Scholar
  81. Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54(9):857–64.PubMedGoogle Scholar
  82. Gimpel GA, Collett BR, Veeder MA, Gifford JA, Sneddon P, Bushman B, et al. Effects of stimulant medication on cognitive performance of children with ADHD. Clin Pediatr. 2005;44(5):405–11.Google Scholar
  83. Golubchik P, Sever J, Zalsman G, Weizman A, Martel MM, Nigg JT, et al. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. Int Clin Psychopharmacol. 2008;23(4):228–31.PubMedGoogle Scholar
  84. Greenfield B, Hechman L. Treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5(1):107–21.PubMedGoogle Scholar
  85. Greenhill LL, Ford RE. Childhood attention-deficit hyperactivity disorder: pharmacological treatments. In: Nathan PE, Gorman JM, editors. A guide to treatments that work. 2nd ed. London: Oxford University Press; 2002. p. 25–55.Google Scholar
  86. Gross-Tsur V, Manor O, Van Der Meere J, Joseph A, Shalev RS. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr. 1997;130(1):40–4.PubMedGoogle Scholar
  87. Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol. 2003;18(2):109–12.PubMedGoogle Scholar
  88. Gunning WB. A controlled trial of clonidine in hyperkinetic children. Rotterdam: Erasmus Universiteit. Proefschrift; 1992.Google Scholar
  89. Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol. 2005;15(6):996–1004.PubMedGoogle Scholar
  90. Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Pediatric Drugs. 2003;5(12):787–94.PubMedGoogle Scholar
  91. Hechtman L, Etcovitch J, Platt R, Arnold LE, Abikoff HB, Newcorn JH, et al. Does multimodal treatment of ADHD decrease other diagnoses? Clin Neurosci Res. 2005;5(5–6):273–82.Google Scholar
  92. Hesdorffer DC, Ludvigsson P, Olafsson E, Gudmundsson G, Kjartansson O, Hauser WA. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry. 2004;61(7):731–6.PubMedGoogle Scholar
  93. Hooberman D, Stern TA. Treatment of attention deficit and borderline personality disorders with psychostimulants: case report. J Clin Psychiatry. 1984;45(10):441–2.PubMedGoogle Scholar
  94. Hunt RD, Lau S. Ryu J. Alternative therapies for ADHD. In: Liebert MA, ed. Ritalin, theory and patient management 1991, pp. 75–96, New York.PubMedGoogle Scholar
  95. Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend. 2008;95(1–2):140–6.PubMedGoogle Scholar
  96. Jensen P. Longer term effects of stimulant treatments for attention-deficit/hyperactivity disorder. J Atten Disord. 2002;6 Suppl 1:S45–56.PubMedGoogle Scholar
  97. Kay GG, Michaels MA, Pakull B. Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine. J Atten Disord. 2009;12(4):316–29.PubMedGoogle Scholar
  98. Kelly K, Ramundo P, Hallowell EM. You mean I am not lazy, stupid or crazy?! The classic selfhelp book for adults with ADHD. Scribner; 2006.Google Scholar
  99. Kessler RC, Adler L, Berkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–23.PubMedGoogle Scholar
  100. Kollins SH, Wilens TE, Fusillo S, Faraone SV, Upadhyaya HP. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord. 2008;12(2):115–25.PubMedGoogle Scholar
  101. Konrad K, Neufang S, Fink GR, Herpertz-Dahlmann B. Long-term effects of methylphenidate on neural networks associated with executive attention in children with ADHD: results from a longitudinal functional MRI study. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1633–41.PubMedGoogle Scholar
  102. Kooij JJS. ADHD bij volwassenen. Inleiding in diagnostiek en behandeling, in Dutch). (ADHD in adults. Introduction to diagnostic assessment and treatment. 2nd ed. Lisse: Swets & Zeitlinger Publishers; 2003.Google Scholar
  103. Kooij JJS. (On medication for adults with ADHD, in Dutch). Over medicatie voor volwassenen met ADHD. Den Haag/Bilthoven: Kenniscentrum ADHD bij volwassenen, PsyQ and Impuls; 2008.Google Scholar
  104. Kooij JJS. ADHD in adults. Clinical studies on assessment and treatment. Thesis, Radboud University Nijmegen, Nijmegen, 2006.Google Scholar
  105. Kooij JJS, Aeckerlin LP, Buitelaar JK. Functioning, comorbidity and treatment of 141 adults with ADHD at an outpatient psychiatric clinic, in Dutch). Ned Tijdschr Geneeskd. 2001;145(31):1498–501.PubMedGoogle Scholar
  106. Kooij JJS, Burger H, Boonstra AM, van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med. 2004;34(6):973–82.PubMedGoogle Scholar
  107. Kooij JJS, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CAT, Hodiamont PPG. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med. 2005;35(6):817–27.PubMedGoogle Scholar
  108. Kooij JS, Boonstra AM, Vermeulen SH, Heister AG, Burger H, Buitelaar JK, et al. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am J Med Genet B Neuropsychiatr Genet. 2008;147B(2):201–8.PubMedGoogle Scholar
  109. Krause KH, Dresel SH, Krause J, la Fougere C, Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev. 2003;27(7):605–13.PubMedGoogle Scholar
  110. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs. 2008;68(13):1803–39.PubMedGoogle Scholar
  111. Levitan RD, Jain UR, Katzman MA. Seasonal affective symptoms in adults with residual attention-deficit hyperactivity disorder. Compr Psychiatry. 1999;40(4):261–7.PubMedGoogle Scholar
  112. Lewy AJ. Melatonin and human chronobiology. Cold Spring Harb Symp Quant Biol. 2007;72:623–36.PubMedGoogle Scholar
  113. Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9(5):380–92.PubMedGoogle Scholar
  114. Lewy AJ, Emens J, Jackman A, Yuhas K. Circadian uses of melatonin in humans. Chronobiol Int. 2006a;23(1–2):403–12.PubMedGoogle Scholar
  115. Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proc Natl Acad Sci USA. 2006b;103(19):7414–9.PubMedGoogle Scholar
  116. Lewy AJ, Rough JN, Songer JB, Mishra N, Yuhas K, Emens JS. The phase shift hypothesis for the circadian component of winter depression. Dialogues Clin Neurosci. 2007;9(3):291–300.PubMedGoogle Scholar
  117. Loo SK, Barkley RA. Clinical utility of EEG in attention deficit hyperactivity disorder. Appl Neuropsychol. 2005;12(2):64–76.PubMedGoogle Scholar
  118. Lovecchio F, Kashani J. Isolated atomoxetine (Strattera) ingestions commonly result in toxicity. J Emerg Med. 2006;31(3):267–8.PubMedGoogle Scholar
  119. Lydon E, El-Mallakh RS. Naturalistic long-term use of methylphenidate in bipolar disorder. J Clin Psychopharmacol. 2006;26(5):516–8.PubMedGoogle Scholar
  120. Medical letter on Daytrana. The medical letter on Drugs and Therapeutics, June 19th, 2006, by the FDA for Daytrana (transdermal methylphenidate patch).PubMedGoogle Scholar
  121. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981–9.PubMedGoogle Scholar
  122. Merkx MJ, Schippers GM, Koeter MJ, Vuijk PJ, Oudejans S, de Vries CC, et al. Allocation of substance use disorder patients to appropriate levels of care: feasibility of matching guidelines in routine practice in Dutch treatment centres. Addiction. 2007;102(3):466–74.PubMedGoogle Scholar
  123. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(8):1412–8.PubMedGoogle Scholar
  124. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477–502.PubMedGoogle Scholar
  125. Murphy KR. Empowering the adult with ADD. In: Nadeau KG, editor. A comprehensive guide to attention deficit disorder in adults: Research, diagnosis, and treatment. Philadelphia: Brunner/Mazel, Inc.; 1995. p. 135–45.Google Scholar
  126. Murray DW, Arnold LE, Swanson J, Wells K, Burns K, Jensen P, et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep. 2008;10(5):424–31.PubMedGoogle Scholar
  127. Nadeau KG. Survival guide for college students with ADD or LD. New York: Magination Press; 1994.Google Scholar
  128. Nadeau K. Adventures in fast forward. Life, love and work for the ADD adult. Brunner/Mazel; 1996.Google Scholar
  129. Najib J. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clin Ther. 2009;31(1):142–76.PubMedGoogle Scholar
  130. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721–30.PubMedGoogle Scholar
  131. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines. Ntp Cerhr Mon. 2005a;16(16):vii–III1.Google Scholar
  132. NTP-CERHR Monograph on the potential human reproductive and developmental effects of methylphenidate. Ntp Cerhr Mon. 2005b;15(15): i–III1.Google Scholar
  133. Ocana AM. Management of cocaine addiction in ADHD. Atten Deficit Hyperact Disord. 2009;1:139.Google Scholar
  134. Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, Hechtman L, Chuang S, Wells KC, Pelham W, Cooper T, Elliott G, Newcorn JH. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry. 2009;48(5):501–10.PubMedGoogle Scholar
  135. Pelham Jr WE, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics. 1990;86(2):226–37.PubMedGoogle Scholar
  136. Pelsser LM, Frankena K, Toorman J, Savelkoul HF, Pereira RR, Buitelaar JK. A randomised controlled trial into the effects of food on ADHD. Eur Child Adolesc Psychiatry. 2009;18(1):12–9.PubMedGoogle Scholar
  137. Pelsser LM, Frankena K, Toorman J, Savelkoul HF, Dubois AE, Pereira RR, Haagen TA, Rommelse NN, Buitelaar JK. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377(9764):494–503.PubMedGoogle Scholar
  138. Pierce D, Dixon CM, Wigal SB, McGough JJ. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. J Child Adolesc Psychopharmacol. 2008;18(4):355–64.PubMedGoogle Scholar
  139. Pietrzak RH, Mollica CM, Maruff P, Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev. 2006;30(8):1225–45.PubMedGoogle Scholar
  140. Poltavski D, Petros T. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits. Physiol Behav. 2006;87(3):614–24.PubMedGoogle Scholar
  141. Quinn P, Nadeau K. Understanding women with ADHD. Silver Spring: Advantage Books; 2002.Google Scholar
  142. Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gomez N, et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs. 2008;22(7):603–11.PubMedGoogle Scholar
  143. Rapoport JL, Inoff-Germain G. Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002. J Atten Disord. 2002;6 Suppl 1:S57–60.PubMedGoogle Scholar
  144. Rapoport JL, Quinn PO, Bradbard G, Riddle KD, Brooks E. Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison. Arch Gen Psychiatry. 1974;30(6):789–93.PubMedGoogle Scholar
  145. Rapport MD, Denney CB. Attention-deficit hyperactivity disorder and methylphenidate: assessment and prediction of clinical response. In: Greenhill LL, Osman BB, editors. Ritalin: theory and practice. 2nd ed. New York: Mary Ann Liebert, Inc.; 2000. p. 45–71.Google Scholar
  146. Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol. 2009;22:22.Google Scholar
  147. Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry. 2005;58(2):125–31.PubMedGoogle Scholar
  148. Ronkainen H, Vakkuri O, Kauppila A. Effects of physical exercise on the serum concentration of melatonin in female runners. Acta Obstet Gynecol Scand. 1986;65(8):827–9.PubMedGoogle Scholar
  149. Rostain AL. Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for management. Postgrad Med. 2008;120(3):27–38.PubMedGoogle Scholar
  150. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadockís comprehensive textbook of psychiatry. Philadelphia: Lippincott, Williams & Wilkins; 2009.Google Scholar
  151. Safren SA, Sprich S, Perlman CA, Otto MW. Mastering your adult ADHD: a cognitive-behavioral treatment program client workbook (Treatments That Work); 2005a.Google Scholar
  152. Safren SA, Sprich S, Perlman CA, Otto MW. Mastering your adult ADHD: a cognitive-behavioral treatment program therapist guide (Treatments That Work); 2005b.Google Scholar
  153. Sandberg S. Hyperactivity and attention disorders of childhood. 2nd ed. Cambridge: Cambridge University Press; 2002.Google Scholar
  154. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29(12):1573–85.PubMedGoogle Scholar
  155. Saul RC. Nortriptyline in attention deficit disorder. Clin Neuropharmacol. 1985;8(4):382–3.PubMedGoogle Scholar
  156. Sawni A. Attention-deficit/hyperactivity disorder and complementary/alternative medicine. Adolesc Med State Art Rev. 2008;19(2):313–26, xi.PubMedGoogle Scholar
  157. Scheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2005;162(1):58–64.PubMedGoogle Scholar
  158. Schuijers F, Kooij JJS. (Adults with ADHD for each other. Support project, in Dutch). (ADHD’ ers voor elkaar. Lotgenotenproject). Bilthoven: Vereniging Impuls; 2007.Google Scholar
  159. Seelen, M. L. & Blom, M. B. J. (2009). Quality of response in bipolar II patients treated with moodstabilisers and stimulants for comorbid ADHD, in Dutch. Internal publication PsyQ, psycho-medical programs.Google Scholar
  160. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205–22.PubMedGoogle Scholar
  161. Sliwinski T, Rozej W, Morawiec-Bajda A, Morawiec Z, Reiter R, Blasiak J. Protective action of melatonin against oxidative DNA damage – chemical inactivation versus base-excision repair. Mutat Res. 2007;634(1–2):220–7.PubMedGoogle Scholar
  162. Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child Neurol. 2001;16(2):86–92.PubMedGoogle Scholar
  163. Solanto MV, Arnsten AFT, Castellanos FX, editors. Stimulant drugs and ADHD: Basic and clinical neuroscience. New York: Oxford University Press; 2001.p. xii, 410pp.Google Scholar
  164. Solhkhah R, Wilens TE, Daly J, Prince JB, Van Patten SL, Biederman J. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol. 2005;15(5):777–86.PubMedGoogle Scholar
  165. Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–32.PubMedGoogle Scholar
  166. Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Gerard K, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775–82.PubMedGoogle Scholar
  167. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456–63.PubMedGoogle Scholar
  168. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006a;61(12):1380–7.PubMedGoogle Scholar
  169. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006b;28(2):266–79.PubMedGoogle Scholar
  170. Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am. 2008;17(2):475–90, xi–xii.PubMedGoogle Scholar
  171. Swanson JM, Hechtman L. Using long-acting stimulants: does it change ADHD treatment outcome? Can Child Adolesc Psychiatr Rev. 2005;14 Suppl 1:2–3.PubMedGoogle Scholar
  172. Swanson JM, Volkow ND. Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behav Brain Res. 2002;130(1–2):73–8.PubMedGoogle Scholar
  173. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the multimodal treatment study of children with ADHD (MTA): part I: executive summary. J Atten Disord. 2008a;12(1):4–14.PubMedGoogle Scholar
  174. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): part II: supporting details. J Atten Disord. 2008b;12(1):15–43.PubMedGoogle Scholar
  175. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223–8.PubMedGoogle Scholar
  176. Thaithumyanon P, Limpongsanurak S, Praisuwanna P, Punnahitanon S. Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant. J Med Assoc Thai. 2005;88(11):1506–13.PubMedGoogle Scholar
  177. Tillman R, Geller B. Controlled study of switching from attention-deficit/hyperactivity disorder to a prepubertal and early adolescent bipolar I disorder phenotype during 6-year prospective follow-up: rate, risk, and predictors. Dev Psychopathol. 2006;18(4):1037–53.PubMedGoogle Scholar
  178. Triolo SJ. Attention deficit hyperactivity disorder in adulthood: a practitioner’s handbook. Philadelphia: Brunner-Routledge; 1999.Google Scholar
  179. Turner D. A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother. 2006;6(4):455–68.PubMedGoogle Scholar
  180. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology. 2003;165(3):260–9.PubMedGoogle Scholar
  181. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55(10):1031–40.PubMedGoogle Scholar
  182. Upadhyaya HP. Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician. Prim Care Companion J Clin Psychiatry. 2008;10(3):211–21.PubMedGoogle Scholar
  183. van de Glind, G., Kooij, J. J. S., Duin, D. v., Goossensen, A. & Carpentier, P. J. (2004). (Protocol ADHD in Addiction. Screening, diagnostic assessment and treatment in outpatient en clinical addiction centers, in Dutch). Utrecht: Trimbos Instituut.Google Scholar
  184. van der Feltz-Cornelis CM, Aldenkamp AP. Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial. Epilepsy Behav. 2006;8(3):659–62.PubMedGoogle Scholar
  185. van der Heijden KB, Smits MG, Van Someren EJW, Gunning WB. Idiopathic chronic sleep onset insomnia in attention-deficit/hyperactivity disorder: a circadian rhythm sleep disorder. Chronobiol Int. 2005;22(3):559–70.PubMedGoogle Scholar
  186. van der Heijden KB, Smits MG, Van Someren EJW, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46(2):233–41.PubMedGoogle Scholar
  187. van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N. Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology. 2009;20(1):60–6.PubMedGoogle Scholar
  188. van Reekum R, Links PS. N of 1 study: methylphenidate in a patient with borderline personality disorder and attention deficit hyperactivity disorder. Can J Psychiatry. 1994;39(3):186–7.PubMedGoogle Scholar
  189. van Veen MM, Kooij JJS, Boonstra AM, Gordijn M, Van Someren EJW. Disrupted circadian rhythm in adults with ADHD and chronic sleep onset insomnia. Biol Psychiatry. 2010;67(11):1091–6.PubMedGoogle Scholar
  190. Verbeeck W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. Adv Ther. 2009;26(2):170–84.PubMedGoogle Scholar
  191. Verster JC, Bekker EM, de Roos M, Minova A, Eijken EJ, Kooij JJ, et al. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial. J Psychopharmacol. 2008;22(3):230–7.PubMedGoogle Scholar
  192. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52(6):456–63.PubMedGoogle Scholar
  193. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6 Suppl 1:S31–43.PubMedGoogle Scholar
  194. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9(6):557–69.PubMedGoogle Scholar
  195. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, et al. Dopamine increases in striatum do not elicit craving in cocaine abusers unless they are coupled with cocaine cues. Neuroimage. 2008;39(3):1266–73.PubMedGoogle Scholar
  196. von Schantz M. Phenotypic effects of genetic variability in human clock genes on circadian and sleep parameters. J Genet. 2008;87(5):513–9.Google Scholar
  197. Waxmonsky JG. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol. 2005;6(5):262–76.PubMedGoogle Scholar
  198. Weber W, Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am. 2007;54(6):983–1006, xii.PubMedGoogle Scholar
  199. Weber W, Vander Stoep A, McCarty RL, Weiss NS, Biederman J, McClellan J. Hypericum perforatum (St Johnís wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. J Am Med Assoc. 2008;299(22):2633–41.Google Scholar
  200. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):35–43.PubMedGoogle Scholar
  201. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625–39.PubMedGoogle Scholar
  202. Weiss G, Hechtman L. Hyperactive children grown up. ADHD in children, adolescents and adults. 2nd ed. New York: Guilford Press; 1993.Google Scholar
  203. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry. 2004;65 Suppl 3:38–45.PubMedGoogle Scholar
  204. Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol. 2007;7:7.Google Scholar
  205. Wilens TE, Biederman J, Mick E, Spencer TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis. 1995a;183(1):48–50.PubMedGoogle Scholar
  206. Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol. 1995b;15(4):270–9.PubMedGoogle Scholar
  207. Wilens TE, Spencer TJ, Biederman J. Pharmacotherapy of adult ADHD. In: Nadeau KG, editor. A comprehensive guide to attention deficit disorder in adults: Research, diagnosis, and treatment. Philadelphia: Brunner/Mazel, Inc.; 1995c. p. 168–88.Google Scholar
  208. Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1147–53.PubMedGoogle Scholar
  209. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158(2):282–8.PubMedGoogle Scholar
  210. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003a;111(1):179–85.PubMedGoogle Scholar
  211. Wilens TE, Prince JB, Spencer T, Van Patten SL, Doyle R, Girard K, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry. 2003b;54(1):9–16.PubMedGoogle Scholar
  212. Wilens T, McBurnett K, Stein M, Lerner M, Spencer T, Wolraich M. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005a;44(10):1015–23.PubMedGoogle Scholar
  213. Wilens TE, Haight BR, Horrigan JP, Hudziak JJ, Rosenthal NE, Connor DF, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry. 2005b;57(7):793–801.PubMedGoogle Scholar
  214. Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005c;66(2):253–9.PubMedGoogle Scholar
  215. Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do? Pediatrics. 2006a;118(3):1215–9.PubMedGoogle Scholar
  216. Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry. 2006b;59(11):1065–70.PubMedGoogle Scholar
  217. Wilens TE, Zusman RM, Hammerness PG, Podolski A, Whitley J, Spencer TJ, et al. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J Clin Psychiatry. 2006c;67(5):696–702.PubMedGoogle Scholar
  218. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend. 2008;96(1–2):145–54.PubMedGoogle Scholar
  219. Wingo AP, Ghaemi SN. Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients. Psychopharmacol Bull. 2008;41(4):37–47.PubMedGoogle Scholar
  220. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2007;120(6):e1494–501.PubMedGoogle Scholar
  221. Wirtz-Justice A, Benedetti F, Terman M. Chronotherapeutics for affective disorders. A clinicianís manual for light and wake therapy. Basel: Karger; 2008.Google Scholar
  222. Wolf U, Golombek U, Diefenbacher A. Diagnosis and treatment of the attention-deficit/hyperactivity syndrome (ADHS) in adults with drug addiction in in-patient and out-patient setting. Psychiatr Prax. 2006;33(5):240–4.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • J. J. Sandra Kooij
    • 1
  1. 1.Program and Expertise Center Adult ADHD PsyQThe HagueThe Netherlands

Personalised recommendations